At the International Psoriasis Council (IPC), we’re a passionate community of researchers and physician experts who share a common goal: improving the health and well-being of people with psoriasis worldwide. We understand the challenges people with psoriasis face and are committed to making a difference.
Our focus is educating health care professionals in psoriasis care management, which aligns with the World Health Organization’s call for improved physician training. We offer clinicians a range of free resources, tools, and information, including live education sessions, webinars, and on-demand videos featuring IPC Board Members and Councilors, renowned opinion leaders in psoriasis.
We are also highly committed to enhancing patient outcomes worldwide by prioritizing research efforts. Our focus is on strengthening the capacity of researchers, promoting collaboration through international partnerships, stakeholder involvement, and evidence-based research, and offering innovative programs and events that support the growth and development of early-career researchers. Together, we can achieve our ultimate goal of improving health care outcomes for all.
IPC was established in 2004 as a United States-based nonprofit organization led by a Board of Directors and supported by a dedicated staff. Our vision is to create a world free of the burden of psoriasis, where people with psoriasis worldwide have access to the best available care and are empowered to lead healthy, fulfilling lives. Our mission is to improve the health and well-being of people with psoriasis and associated diseases worldwide through education, research, and advocacy. We’re excited about the future and look forward to making a positive impact.
We believe that psoriasis patients, no matter where they live in the world, no matter how complex their symptoms, should have access to the best care available to them. Please join us in making this possible.
IPC Jr. Councilor Towhida Noor reviews the psoriasis pipeline: selective TYK2 inhibitors, long-acting IL-17 and IL-23 biologics, and IL-36 blockade in GPP.
IPC Board Member and Treasurer Joel Gelfand, MD, MSCE, is the editor of a new textbook, Psoriasis: An Expert Global Perspective, now available for preorder from Elsevier. He worked with associate editors IPC President Bruce Strober, MD, PhD; IPC Vice President/President-Elect Claudia de la Cruz, MD; and IPC Chief Medical Officer Peter van de Kerkhof, MD, PhD. Nearly 50 authors from 20 countries contributed 30 chapters covering psoriasis from its earliest descriptions through genetics, immunology, and current therapies, with clinical images of psoriasis across diverse skin tones. All royalties support IPC.
PRE-ORDER YOUR COPY
In this video, IPC Councilor Rodrigo Garcia Salinas, MD, a rheumatologist from Argentina, explains how to recognize psoriatic arthritis early, including why joint pain, how long a patient has had psoriasis, and family history can matter more than skin severity alone. He also reviews how imaging helps catch early disease and how to choose treatment based on each patient’s joint, spine, and skin involvement.
IPC President Bruce Strober reviews the link between psoriasis and metabolic disease, drawing on findings from IPC’s recent paper in the Journal of the American Academy of Dermatology (JAAD). He translates this growing body of evidence into five concrete priorities from the 2025 IPC Think Tank for improving cardiometabolic screening and care.
